# A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body

> **NCT05564104** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 32 (actual)

## Conditions studied

- Hepatic Impairment
- Healthy Volunteers

## Interventions

- **DRUG:** Cagrilintide

## Key facts

- **NCT ID:** NCT05564104
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-05
- **Primary completion:** 2024-09-06
- **Final completion:** 2024-12-19
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05564104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05564104, "A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT05564104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*